Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution
International Journal of Cancer · 2026
DOI: 10.1002/ijc.35327 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Kira Furlano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Charité- Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Precision Medicine, Chromatin, Epigenomics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Ontario Institute for Cancer Research, Foundation of Urological Research (Stiftung Urologische Forschung).
Abstract (Originalsprache)
Prostate cancer is a common malignancy that in 5%–30% leads to treatment‐resistant and highly aggressive disease. Metastasis‐potential and treatment‐resistance is thought to rely on increased plasticity of the cancer cells—a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create cellular heterogeneity. To understand the molecular basis of this plasticity, genomic studies have uncovered genetic variants to capture clonal heterogeneity of primary tumors and metastases. As cellular plasticity is largely driven by non‐genetic events, complementary studies in cancer epigenomics are now being conducted to identify chromatin variants . These variants, defined as genomic loci in cancer cells that show changes in chromatin state due to the loss or gain of epigenomic marks, inclusive of histone post‐translational modifications, DNA methylation and histone variants, are considered the fundamental units of epigenomic heterogeneity. In prostate cancer chromatin variants hold the promise of guiding the new era of precision oncology. In this review, we explore the role of epigenomic heterogeneity in prostate cancer, focusing on how chromatin variants contribute to tumor evolution and therapy resistance. We therefore discuss their impact on cellular plasticity and stochastic events, highlighting the value of single‐cell sequencing and liquid biopsy epigenomic assays to uncover new therapeutic targets and biomarkers. Ultimately, this review aims to support a new era of precision oncology, utilizing insights from epigenomics to improve prostate cancer patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Charité- Universitätsmedizin Berlin, Berlin, Germany.
- Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
- Department of Medical Biophysics, University of Toronto, Toronto, Canada.
- Department of Urology, Medical University of Vienna, Vienna, Austria.
- Biotech Research & Innovation Centre (BRIC), The Finsen Laboratory, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
ORCID-Profile: Kira Furlano
Förderung
- CIHR
- Ontario Institute for Cancer Research
- Foundation of Urological Research (Stiftung Urologische Forschung)
- Canadian Institutes of Health Research
Zitieren
APA
Furlano, K., Keshavarzian, T., Biernath, N., Fendler, A., de Santis, M., Weischenfeldt, J., & Lupien, M. (2026). Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution. International Journal of Cancer. https://doi.org/10.1002/ijc.35327
Vancouver
Furlano K, Keshavarzian T, Biernath N, Fendler A, de Santis M, Weischenfeldt J, et al. Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution. International Journal of Cancer. 2026. doi:10.1002/ijc.35327
BibTeX
@article{Furlano2026,
author = {Furlano, Kira and Keshavarzian, Tina and Biernath, Nadine and Fendler, Annika and de Santis, Maria and Weischenfeldt, Joachim and Lupien, Mathieu},
title = {Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.35327}
}
EUVIMED